137 related articles for article (PubMed ID: 24626632)
1. Eccentric muscle challenge shows osteopontin polymorphism modulation of muscle damage.
Barfield WL; Uaesoontrachoon K; Wu CS; Lin S; Chen Y; Wang PC; Kanaan Y; Bond V; Hoffman EP
Hum Mol Genet; 2014 Aug; 23(15):4043-50. PubMed ID: 24626632
[TBL] [Abstract][Full Text] [Related]
2. SPP1 genotype and glucocorticoid treatment modify osteopontin expression in Duchenne muscular dystrophy cells.
Vianello S; Pantic B; Fusto A; Bello L; Galletta E; Borgia D; Gavassini BF; Semplicini C; Sorarù G; Vitiello L; Pegoraro E
Hum Mol Genet; 2017 Sep; 26(17):3342-3351. PubMed ID: 28595270
[TBL] [Abstract][Full Text] [Related]
3. TGFBR2 but not SPP1 genotype modulates osteopontin expression in Duchenne muscular dystrophy muscle.
Piva L; Gavassini BF; Bello L; Fanin M; Soraru G; Barp A; Ermani M; Angelini C; Hoffman EP; Pegoraro E
J Pathol; 2012 Oct; 228(2):251-9. PubMed ID: 22431140
[TBL] [Abstract][Full Text] [Related]
4. Alterations in osteopontin modify muscle size in females in both humans and mice.
Hoffman EP; Gordish-Dressman H; McLane VD; Devaney JM; Thompson PD; Visich P; Gordon PM; Pescatello LS; Zoeller RF; Moyna NM; Angelopoulos TJ; Pegoraro E; Cox GA; Clarkson PM
Med Sci Sports Exerc; 2013 Jun; 45(6):1060-8. PubMed ID: 23274598
[TBL] [Abstract][Full Text] [Related]
5. OPN-a induces muscle inflammation by increasing recruitment and activation of pro-inflammatory macrophages.
Many GM; Yokosaki Y; Uaesoontrachoon K; Nghiem PP; Bello L; Dadgar S; Yin Y; Damsker JM; Cohen HB; Kornegay JN; Bamman MM; Mosser DM; Nagaraju K; Hoffman EP
Exp Physiol; 2016 Oct; 101(10):1285-1300. PubMed ID: 27452303
[TBL] [Abstract][Full Text] [Related]
6. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy.
Pegoraro E; Hoffman EP; Piva L; Gavassini BF; Cagnin S; Ermani M; Bello L; Soraru G; Pacchioni B; Bonifati MD; Lanfranchi G; Angelini C; Kesari A; Lee I; Gordish-Dressman H; Devaney JM; McDonald CM;
Neurology; 2011 Jan; 76(3):219-26. PubMed ID: 21178099
[TBL] [Abstract][Full Text] [Related]
7. Neopterin/7,8-dihydroneopterin is elevated in Duchenne muscular dystrophy patients and protects mdx skeletal muscle function.
Lindsay A; Schmiechen A; Chamberlain CM; Ervasti JM; Lowe DA
Exp Physiol; 2018 Jul; 103(7):995-1009. PubMed ID: 29791760
[TBL] [Abstract][Full Text] [Related]
8. Osteopontin is linked with AKT, FoxO1, and myostatin in skeletal muscle cells.
Nghiem PP; Kornegay JN; Uaesoontrachoon K; Bello L; Yin Y; Kesari A; Mittal P; Schatzberg SJ; Many GM; Lee NH; Hoffman EP
Muscle Nerve; 2017 Dec; 56(6):1119-1127. PubMed ID: 28745831
[TBL] [Abstract][Full Text] [Related]
9. The functional -443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor.
Schultz J; Lorenz P; Ibrahim SM; Kundt G; Gross G; Kunz M
Mol Carcinog; 2009 Jan; 48(1):14-23. PubMed ID: 18459127
[TBL] [Abstract][Full Text] [Related]
10. IL6 (-174) and TNFA (-308) promoter polymorphisms are associated with systemic creatine kinase response to eccentric exercise.
Yamin C; Duarte JA; Oliveira JM; Amir O; Sagiv M; Eynon N; Sagiv M; Amir RE
Eur J Appl Physiol; 2008 Oct; 104(3):579-86. PubMed ID: 18758806
[TBL] [Abstract][Full Text] [Related]
11. Osteopontin and interleukin-17A genes polymorphisms in Egyptian systemic lupus erythematosus patients: A relation to disease activity and severity.
Pasha HF; Tantawy EA; Youssef MA
Gene; 2019 Jun; 702():107-113. PubMed ID: 30898714
[TBL] [Abstract][Full Text] [Related]
12. Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy.
Bello L; Piva L; Barp A; Taglia A; Picillo E; Vasco G; Pane M; Previtali SC; Torrente Y; Gazzerro E; Motta MC; Grieco GS; Napolitano S; Magri F; D'Amico A; Astrea G; Messina S; Sframeli M; Vita GL; Boffi P; Mongini T; Ferlini A; Gualandi F; Soraru' G; Ermani M; Vita G; Battini R; Bertini E; Comi GP; Berardinelli A; Minetti C; Bruno C; Mercuri E; Politano L; Angelini C; Hoffman EP; Pegoraro E
Neurology; 2012 Jul; 79(2):159-62. PubMed ID: 22744661
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in the osteopontin promoter affect its transcriptional activity.
Giacopelli F; Marciano R; Pistorio A; Catarsi P; Canini S; Karsenty G; Ravazzolo R
Physiol Genomics; 2004 Dec; 20(1):87-96. PubMed ID: 15479859
[TBL] [Abstract][Full Text] [Related]
14. Skeletal Muscle Differentiation on a Chip Shows Human Donor Mesoangioblasts' Efficiency in Restoring Dystrophin in a Duchenne Muscular Dystrophy Model.
Serena E; Zatti S; Zoso A; Lo Verso F; Tedesco FS; Cossu G; Elvassore N
Stem Cells Transl Med; 2016 Dec; 5(12):1676-1683. PubMed ID: 27502519
[TBL] [Abstract][Full Text] [Related]
15. Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis.
Chen Y; Liu H; Wu W; Li Y; Li J
J Exp Clin Cancer Res; 2013 Jul; 32(1):45. PubMed ID: 23883434
[TBL] [Abstract][Full Text] [Related]
16. Osteopontin, Bone Morphogenetic Protein-4, and Vitamin D Receptor Gene Polymorphisms in the Susceptibility and Clinical Severity of Spinal Tuberculosis.
Wang G; Xie L; Hu J; Lu H; Liu X; Cao Y; Liu B; Zhang Y; Shen X
Cell Physiol Biochem; 2017; 41(5):1881-1893. PubMed ID: 28376475
[TBL] [Abstract][Full Text] [Related]
17. Potent pro-inflammatory and pro-fibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin α2 chain-deficient muscular dystrophy.
Gawlik KI; Holmberg J; Svensson M; Einerborg M; Oliveira BM; Deierborg T; Durbeej M
Sci Rep; 2017 Mar; 7():44059. PubMed ID: 28281577
[TBL] [Abstract][Full Text] [Related]
18. Serum Osteopontin as a Novel Biomarker for Muscle Regeneration in Duchenne Muscular Dystrophy.
Kuraoka M; Kimura E; Nagata T; Okada T; Aoki Y; Tachimori H; Yonemoto N; Imamura M; Takeda S
Am J Pathol; 2016 May; 186(5):1302-12. PubMed ID: 26963343
[TBL] [Abstract][Full Text] [Related]
19. The impact of osteopontin promoter polymorphisms on the risk of calcium urolithiasis.
Liu CC; Huang SP; Tsai LY; Wu WJ; Juo SH; Chou YH; Huang CH; Wu MT
Clin Chim Acta; 2010 May; 411(9-10):739-43. PubMed ID: 20144595
[TBL] [Abstract][Full Text] [Related]
20. The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis.
Chiu YW; Tu HF; Wang IK; Wu CH; Chang KW; Liu TY; Kao SY
Oral Oncol; 2010 Apr; 46(4):302-6. PubMed ID: 20219412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
